NCT05823675 - Safety and Clinical Activity of Itolizumab in aGVHD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

February 28, 2025

Conditions

Acute Graft Versus Host Disease

Interventions

DRUG

Itolizumab

Subjects will receive Itolizumab concomitant within 72 hours of systematic Corticosteroids.

DRUG

Methylprednisolone

Methylprednisolone will be taperred as required

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin